Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Glaucoma device developer Transcend raises $20mm Series B; closes round at $51mm

Executive Summary

Transcend Medical, which is developing the minimally invasive stent CyPass to reduce intra-ocular pressure from glaucoma, has raised $20mm out of a potential $40mm in Series B financing, according to the Form D filing. First-time backer HLM Venture Partners led and was joined by other new investors Canaan Partners, Technology Partners, and Latterell Venture Partners. Existing shareholders Morgenthaler Ventures and Split Rock Partners also participated.
Deal Industry
  • Medical Devices
  • Medical Devices
    • Implantable Devices
    • Surgical Equipment & Devices
      • Minimally or Less Invasive
Deal Status
  • Final
Deal Type
  • Financing
    • Venture Financing

Related Companies